Kersti Oselin
About
Kersti Oselin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, Kersti Oselin has authored 41 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kersti Oselin's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Kersti Oselin is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Kersti Oselin collaborates with scholars based in Estonia, Germany and United Kingdom. Kersti Oselin's co-authors include Ivar Roots, P.M. Mrozikiewicz, Thomas Gerloff, Rein Pähkla, Kaili Anier, Christian Meisel, Tuuli Metsvaht, Ingolf Cascorbi, Andreas Johne and Karin Kipper and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and Annals of Oncology.
In The Last Decade
Kersti Oselin
39 papers receiving 708 citations
Peers
Kersti Oselin
May Fakhoury France
Thomas Storme France
Aurélie Prémaud France
Robin Michelet Germany
Karin Dilger Germany
Robert R. Mayo United States
P. Le Pogamp France
Azemi Barama Canada
Marie‐Claude Gagnieu France
K L Heim-Duthoy United States
Citations per year, relative to Kersti Oselin Kersti Oselin (= 1×)
peers
May Fakhoury
Countries citing papers authored by Kersti Oselin
Since
Specialization
Citations
This map shows the geographic impact of Kersti Oselin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kersti Oselin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kersti Oselin more than expected).
Fields of papers citing papers by Kersti Oselin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kersti Oselin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kersti Oselin. The network helps show where Kersti Oselin may publish in the future.
Co-authorship network of co-authors of Kersti Oselin
This figure shows the co-authorship network connecting the top 25 collaborators of Kersti Oselin. A scholar is included among the top collaborators of Kersti Oselin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kersti Oselin. Kersti Oselin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schil, Paul E. Van, M. Pérol, Kersti Oselin, et al.. (2025). 175TiP: ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC. Journal of Thoracic Oncology. 20(3). S118–S119.
2.
Tagliamento, Marco, Marie Morfouace, Júlio Oliveira, et al.. (2024). EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers. npj Precision Oncology. 8(1). 37–37.
3.
Hochmair, Maximilian J., Mojca Unk, Timur Cerić, et al.. (2024). Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. BMC Proceedings. 18(S3). 2–2.
4.
Baum, Philip, Rafael Cardoso, Jacopo Lenzi, et al.. (2024). An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations. European Journal of Cancer. 209. 114233–114233.
5.
Morfouace, Marie, Daniel Schulz, Nils Eling, et al.. (2023). 2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort. Annals of Oncology. 34. S1164–S1164.
6.
Besse, Benjamin, Libor Havel, Solange Peters, et al.. (2023). 120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091. Immuno-Oncology Technology. 20. 100592–100592.
7.
Paz-Ares, L., E O’Brien, M. Mauer, et al.. (2022). VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. Annals of Oncology. 33(4). 451–453.
8.
Peters, Solange, Sandrine Marréaud, Urania Dafni, et al.. (2022). 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091. Annals of Oncology. 33. S971–S972.
9.
Oselin, Kersti, et al.. (2019). Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience. Journal of Thoracic Disease. 11(2). 456–464.
10.
Paz‐Ares, Luis, Baktiar Hasan, Urania Dafni, et al.. (2017). A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS). Annals of Oncology. 28. ii23–ii23.
11.
Oselin, Kersti, et al.. (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?. BMC Pediatrics. 16(1). 206–206.
12.
Metsvaht, Tuuli, et al.. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology. 100(2). 111–115.
13.
Tamm, Riin, Kersti Oselin, Reedik Mägi, et al.. (2008). Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clinical Chemistry and Laboratory Medicine (CCLM). 46(7). 974–9.
14.
Karjagin, Juri, Sandrine Lefeuvre, Kersti Oselin, et al.. (2007). Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock. Clinical Pharmacology & Therapeutics. 83(3). 452–459.
15.
Oselin, Kersti, et al.. (2006). Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian population using HPLC-UV assay. Journal of Chromatography B. 834(1-2). 77–83.
16.
Oselin, Kersti, P.M. Mrozikiewicz, Rein Pähkla, & Ivar Roots. (2003). Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS‐sorted peripheral blood CD4+, CD8+, CD19+, and CD56+cells. European Journal Of Haematology. 71(2). 119–123.
17.
Oselin, Kersti, et al.. (2003). Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. European Journal of Clinical Pharmacology. 59(4). 347–350.
18.
Oselin, Kersti, et al.. (2003). Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. European Journal of Clinical Investigation. 33(3). 261–267.
19.
Oselin, Kersti, Thomas Gerloff, P.M. Mrozikiewicz, Rein Pähkla, & Ivar Roots. (2003). MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental and Clinical Pharmacology. 17(4). 463–469.
20.
Gerloff, Thomas, Andreas Johne, Kersti Oselin, et al.. (2002). MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British Journal of Clinical Pharmacology. 54(6). 610–616.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by May Fakhoury Breakdown of academic impact, for papers by Thomas Storme Breakdown of academic impact, for papers by Aurélie Prémaud Breakdown of academic impact, for papers by Robin Michelet Breakdown of academic impact, for papers by Karin Dilger Breakdown of academic impact, for papers by Robert R. Mayo Breakdown of academic impact, for papers by P. Le Pogamp Breakdown of academic impact, for papers by Azemi Barama Breakdown of academic impact, for papers by Marie‐Claude Gagnieu Breakdown of academic impact, for papers by K L Heim-Duthoy